The Global X-Linked Hypophosphatemia Market, by treatment, has been segmented into medication, corrective surgery, and dental procedures. Medication has been further segmented into oral phosphate supplements and vitamin D, growth hormones and others.
The Global X-Linked Hypophosphatemia Market is expected to grow significantly over the forecast period. It is estimated that the global X–linked hypophosphatemia market is expected to grow during the forecast period, 2018 to 2023.
X-Linked Hypophosphatemia (XLH) is a genetic disorder characterized by low levels of phosphate in the blood. Phosphate levels in the blood are low as phosphate is abnormally processed in kidneys, which causes a loss of phosphate in urine and leads to soft and weak bones. The growing prevalence of X-linked hypophosphatemia, increasing healthcare expenditure, and rising prevalence of genetic diseases are anticipated to drive the growth of the market.
According to a press release by the US Food & Drug Administration (FDA) in April 2018, X-Linked Hypophosphatemia (XLH) is a serious disease affecting approximately 3,000 children and 12,000 adults in the US. Despite the drivers, limited treatment options for the disorder may hamper the growth of the market during the assessment period.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/6267 .
Global X-Linked Hypophosphatemia Market, by Key Players
Ultragenyx Pharmaceutical Inc.
Kyowa Hakko Kirin Co. Ltd.
Validus Pharmaceuticals LLC
Merck & Co., Inc.
Hoffmann-La Roche Ltd.
Koninklijke DSM N.V.
ADM Alliance Nutrition, Inc.
Eli Lily and Company
X-Linked Hypophosphatemia Market Segmentation
The Global X-Linked Hypophosphatemia Market has been segmented into symptom, diagnosis, treatment, and end-user. The market on the basis of symptom has been segmented into bone pain, muscle pain, short stature, abnormal tooth development, tooth abscesses and dental pain, craniosynostosis, and others.
The market, by diagnosis, has been segmented into blood test, urine test, genetic test, bone x-ray, and others. The market, by treatment, has been segmented into medication, corrective surgery, and dental procedures. Medication has been further segmented into oral phosphate supplements and vitamin D, growth hormones, and others.
On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.
The market in the Americas is expected to dominate the global X-linked hypophosphatemia market during the forecast period owing to the increasing prevalence of XLH and well-established healthcare sector in the region. The European market is expected to be the second-largest due to government funding and support of the healthcare sector, increasing research and development, and rising prevalence of X-linked hypophosphatemia in the region. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing market during the forecast period owing to technological developments and favorable government initiatives for healthcare facilities. The market in the Middle East and Africa is likely to account for the smallest share of the global X-linked hypophosphatemia market. The market growth in this region can be attributed to the increasing healthcare expenditure and low manufacturing costs of pharmaceuticals.
Get Discount @ https://www.marketresearchfuture.com/check-discount/6267 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312